NCT07507175 Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis
| NCT ID | NCT07507175 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-01-03 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-01-03 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether gastrocnemius myofascial release is effective in reducing pain and improving physical function in females with knee osteoarthritis. The main question this study aims to answer are: * Does adding gastrocnemius MFR to conventional physical therapy treatment influence pain, physical function, foot posture, and knee disability compared to conventional physical therapy treatment and sham MFR in knee osteoarthritis? * Participants receive gastrocnemius myofascial release treatment or sham gastrocnemius myofascial release treatment for 3 times weekly for 4 weeks for both groups.
Eligibility Criteria
Inclusion Criteria: * Patients' ages ranged between 45 and 55 years . * BMI ≤35 * Patients with a diagnosis of primary KOA according to the American College of Rheumatology classification at the screening visit . * Onset of symptomatic knee osteoarthritis of ≥3 months * Patients with grade II and III OA of the Kellgren and Lawrence system for classification of osteoarthritis . * At least one active trigger point in GM * If both knees were diagnosed as OA, the most affected one was selected. * Current pain intensity on the Visual Analogue Scale (VAS) ≥4/10. * Subjects have sufficient cognition that enables them to understand the requirements of the study, comply with the study procedures, and visit schedule. * Diagnostic Criteria of KOA A diagnosis of knee osteoarthritis was made when knee pain is present, plus Osteophytes on radiographs, plus at least 1 of the following 3: * Age \> 50 years * Morning stiffness \< 30 minutes * Crepitus on active motion Exclusion Criteria: * Patients with any previous knee surgeries or lower limb fractures. * Chronic inflammatory diseases such as rheumatoid arthritis. * Signs of moderately significant knee synovitis include a warm and swollen (red) knee * History and/or physical examination findings compatible with knee internal derangement (e.g, positive Thessaly test). * Pregnancy * Patients who had undergone arthroscopy or treatment with intra-articular hyaluronic acid during the previous 6 months . * Use of NSAIDs one week before the screening visit . * Orthopedic diseases, or congenital musculoskeletal deformities, or neurological disorders that may affect or interfere with the therapeutic effect. * Participated in other intervention studies (strength training program or physiotherapy treatment for knee osteoarthritis) in the current period and the past 6 months . * Habitual use of psychotropic or narcotic analgesics for ≥1 week within 8 weeks prior to screening .
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07507175 clinical trial?
This trial is open to female participants only, aged 45 Years or older, up to 55 Years, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07507175 currently recruiting?
Yes, NCT07507175 is actively recruiting participants. Contact the research team at hendhammam18@live.com for enrollment information.
Where is the NCT07507175 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT07507175 clinical trial?
NCT07507175 is sponsored by Cairo University. The trial plans to enroll 30 participants.